Isotechnika Inc.

January 24, 2007 11:01 ET

Isotechnika Inc. Increases Size of Bought Deal to $35,150,000

EDMONTON, ALBERTA--(CCNMatthews - Jan. 24, 2007) -


Isotechnika Inc. (TSX:ISA) is pleased to announced that the syndicate of underwriters led by GMP Securities L.P., and including Canaccord Capital Corporation, RBC Dominion Securities Inc. and National Bank Financial Inc., have increased the size of the previously announced bought deal by an additional 4,000,000 units ("Units") of the Company at a price of $1.85 per Unit, all on the terms set forth in the Company's earlier press release. The total size of the deal is now 19,000,000 Units for aggregate gross proceeds for the Company of $35,150,000 (the "Offering") and the underwriters will also have an option, exercisable for a period of 30 days following the closing date, to purchase from the Company up to an additional 2,850,000 Units for gross proceeds of $40,422,500 to cover over-allotments. The Company intends to use the net proceeds of the Offering for clinical trial expenses, working capital and general corporate purposes.

The securities offered have not been registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful.

About Isotechnika Inc.

Isotechnika Inc. is an international biopharmaceutical company headquartered in Edmonton, Alberta, Canada. Drawing upon its expertise in medicinal chemistry and immunology, the Company is focused on the discovery and development of novel immunosuppressive therapeutics that are safer than currently available treatments. Its entrepreneurial management and world-class team of scientists are building a pipeline of immunosuppressive drug candidates for treatment of autoimmune diseases and for use in the prevention of organ rejection in transplantation. Isotechnika looks to become the leader in development of immunosuppressant therapies.

Isotechnika's lead compound, ISA247 has successfully completed a Phase III Canadian trial for the treatment of moderate to severe psoriasis. ISA247 is currently being investigated in a combined Phase III European/Canadian psoriasis trial and a Phase IIb North American trial for the prevention of kidney graft rejection. The Company also has an additional immunosuppressive compound in its drug pipeline, TAFA93 which successfully completed Phase I clinical trials.

Isotechnika Inc. is a publicly traded company on the Toronto Stock Exchange under the symbol "ISA". More information on Isotechnika can be found at

Contact Information